Regulus Therapeutics Inc
RGLS
Market Cap$103.44M
Close$
$0.68
91.6% downside
Current Fair Value
91.6% downsideOvervalued by 91.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $103.44 Million |
|---|---|
| Enterprise Value | $55.58 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.58 |
| Beta | 1.62 |
| Outstanding Shares | 64,465,185 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.88 |
|---|---|
| PEG | -20.92 |
| Price to Sales | - |
| Price to Book Ratio | 8.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.09 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Regulus Therapeutics Inc
24 employees
CEO: Joseph Hagan Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop ...